SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (2462)9/17/1997 8:38:00 PM
From: Pseudo Biologist   of 9719
 
More on DNEX/MDYN

After the first post, I talked some with the experts (people who use this stuff) and they would go with MDYN. DNEX's markets are not growing as much, they compete directly with Perkin Elmer (the buyer of PBIO) and the chromatography division of HP; they do have a unique product for analysis of carbohydrates and glycoproteins. MDYN's markets are growing faster; their current star product is a densitomer said to be the coolest thing since the web -g-

Andrew, thanks for the Inflazyme link. And yes, Xoma is hot. This company has always had excellent science and technology (e.g., they are getting a piece of IDEC's drug as they were the first to make chimeric anti-CD20, but did not pursue it ...) but not so good business people; maybe they learned this time and maybe this BPI does work.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News